125 related articles for article (PubMed ID: 22759092)
21. Intergroup Exemestane Study mature analysis: overall survival data.
Jassem J;
Anticancer Drugs; 2008 Feb; 19 Suppl 1():S3-7. PubMed ID: 18340242
[TBL] [Abstract][Full Text] [Related]
22. DCIS and aromatase inhibitors.
Dixon JM; Faratian D; White S; Renshaw L; Murray J; Young O; Macaskill EJ; Williams L; Thomas J; Evans DB
J Steroid Biochem Mol Biol; 2007; 106(1-5):173-9. PubMed ID: 17604618
[TBL] [Abstract][Full Text] [Related]
23. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
24. Are SOFT and TEXT results practice changing and how?
Pagani O; Regan MM; Francis PA
Breast; 2016 Jun; 27():122-5. PubMed ID: 27107153
[TBL] [Abstract][Full Text] [Related]
25. Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Gemignani ML; Hetzel DJ
Gynecol Oncol; 2017 Oct; 147(1):153-157. PubMed ID: 28662774
[No Abstract] [Full Text] [Related]
26. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
Hutchinson L
Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
[No Abstract] [Full Text] [Related]
27. [Lobular carcinoma-in-situ and ductal hyperplasia of breast].
Fu L
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):4-7. PubMed ID: 16608640
[No Abstract] [Full Text] [Related]
28. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Ingle JN
Steroids; 2011 Jul; 76(8):765-7. PubMed ID: 21382394
[TBL] [Abstract][Full Text] [Related]
29. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
30. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Jakesz R
MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
[No Abstract] [Full Text] [Related]
31. Targeting breast cancer with hormonal treatment options.
Mellington TE; Fields MM
Nurse Pract; 2008 May; 33(5):17-22; quiz 22-3. PubMed ID: 18458623
[No Abstract] [Full Text] [Related]
32. [New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant radiotherapy for DCIS.
Joseph DJ; Spry N; Bydder S
Lancet; 2000 Jun; 355(9220):2072; author reply 2072-3. PubMed ID: 10885376
[No Abstract] [Full Text] [Related]
34. Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Herold CI; Blackwell KL
Clin Breast Cancer; 2008 Feb; 8(1):50-64. PubMed ID: 18501059
[TBL] [Abstract][Full Text] [Related]
35. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
[TBL] [Abstract][Full Text] [Related]
37. Ductal carcinoma-in-situ.
Wickerham DL
J Clin Oncol; 2001 Sep; 19(18 Suppl):98S-100S. PubMed ID: 11560982
[No Abstract] [Full Text] [Related]
38. To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
Iddon J; Bundred NJ
Expert Rev Anticancer Ther; 2008 Jan; 8(1):9-13. PubMed ID: 18095878
[TBL] [Abstract][Full Text] [Related]
39. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC; Kilburn LS; Snowdon CF; Paridaens R; Coleman RE; Jones SE; Jassem J; Van de Velde CJ; Delozier T; Alvarez I; Del Mastro L; Ortmann O; Diedrich K; Coates AS; Bajetta E; Holmberg SB; Dodwell D; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Forbes J; Castiglione M; Stuart N; Stewart A; Fallowfield LJ; Bertelli G; Hall E; Bogle RG; Carpentieri M; Colajori E; Subar M; Ireland E; Bliss JM;
Lancet; 2007 Feb; 369(9561):559-70. PubMed ID: 17307102
[TBL] [Abstract][Full Text] [Related]
40. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
